Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 375-381

  Klaeffling, C ^a   Piechottka, G ^b   Daemgen Von Brevern, G ^a   Mosch, G ^a   Mani, H ^a   Luxembourg, B ^a   Lindhoff Last, E ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Haemochrom Diagnostica GmbH   (Germany)

^c NONE   (Germany)

Author keywords

Anticoagulant; Chromogenic assay; Factor Xa; Fondaparinux

Indexed keywords

ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; CREATININE; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; ANTICOAGULATION; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; EX VIVO STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; MALE; ORTHOPEDIC SURGERY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REPRODUCIBILITY; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS;

ANTICOAGULANTS; ANTITHROMBIN III; CHROMOGENIC COMPOUNDS; DRUG MONITORING; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PHENPROCOUMON; POLYSACCHARIDES; REPRODUCIBILITY OF RESULTS; VITAMIN K;

EID: 33748140686     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000196662.35726.0f     Document Type: Article

References (15)

1. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
2. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
3. Lassen MR, Bauer KA, Erikssen BI, et al. Postoperative Fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double blind trial. Lancet. 2002;359:1715-1720.
4. Buller HR, Davidson BL, Decousus H, et al. Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867-873.
5. Buller HR, Davidson BL, Decousus H, et al. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-1702.
6. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107/ORG-31540) with high affinity to antithrombin III in man. Thromb Haemost. 1995;74:1468-1473.
7. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to AT mediated neutralization of Factor Xa. Thromb Haemost. 1995;74:1474-1477.
8. Petitou M, Duchaussoy P, Herbert JM, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost. 2002;28:393-402.
9. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107 A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997;15:1-26.
10. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(Suppl 2):1-9.
11. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra®) in the dually perfused cotyledon in vitro. Thromb Haemost. 2002;87:831-835.
12. Paolucci F, Frasa H, Van Aarle F, et al. Two sensitive and rapid chromogenic assays of Fondaparinux Sodium (Arixtra®) in human plasma and other biological matrices. Clin Lab. 2003;49:451-460.
13. Depasse F, Geroziafas T, Busson J, et al. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra®) anti-Xa activity. J Thromb Haemost. 2003;2:346-379.
14. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl):188S-203S.
15. The Rembrand Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. Circulation. 2000;102:2726-2731.